Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Lili Chu
Fragment-Based Drug Design and Identification of HJC0123 , a Novel Orally Bioavailable STAT3 Inhibitor for Cancer Therapy
European Journal of Medicinal Chemistry
Medicine
Organic Chemistry
Drug Discovery
Pharmacology
Related publications
Discovery of Potent Anticancer Agent HJC0416, an Orally Bioavailable Small Molecule Inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3)
European Journal of Medicinal Chemistry
Medicine
Organic Chemistry
Drug Discovery
Pharmacology
Discovery of Novel KRAS-PDE Inhibitors by Fragment-Based Drug Design
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
Targeting Constitutively-Activated STAT3 in Hypoxic Ovarian Cancer, Using a Novel STAT3 Inhibitor
Oncoscience
Cancer Research
Oncology
In Silico Approaches for Fragment-Based Drug Design
Yakugaku Zasshi
Pharmacology
Pharmaceutical Science
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable Γ-Secretase Inhibitor
ACS Medicinal Chemistry Letters
Organic Chemistry
Biochemistry
Drug Discovery
Design and Synthesis of Novel Isoquinoline-3-Nitriles as Orally Bioavailable Kv1.5 Antagonists for the Treatment of Atrial Fibrillation
A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets
Frontiers in Neurology
Neurology
Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
PLoS ONE
Multidisciplinary
